The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
-
Advanced Cardiovascular LLC, Alexander City, Alabama, United States, 35010
Eastern Shore Research Institute, Fairhope, Alabama, United States, 36532
Heart Center Research LLC, Huntsville, Alabama, United States, 35801
CB Flock Research Corporation, Mobile, Alabama, United States, 36608
Eclipse Clinical Research, Tucson, Arizona, United States, 85745
310 Clinical Research, Inglewood, California, United States, 90301
Valley Clinical Trials, Northridge, California, United States, 91325
Clinical Trials Research - Sacramento, Roseville, California, United States, 95661
Acclaim Clinical Research, San Diego, California, United States, 92120
Diablo Clinical Research, Walnut Creek, California, United States, 94598
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
50 Years to 105 Years
ALL
No
Amgen,
MD, STUDY_DIRECTOR, Amgen
2031-10-18